Virus-like Particles Market
Number of pages: 100 | Report Format: PDF | Published date: March 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 4.96 billion |
|
Revenue Forecast in 2031 |
US$ 9.80 billion |
|
CAGR |
7.85% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Source, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global virus-like particles market was valued at US$ 4.96 billion in 2022 and is expected to register a revenue CAGR of 7.85% to reach US$ 9.80 billion by 2031.
Virus-like Particles Market Fundamentals
Virus-like particles (VLPs) are structures that mimic the shape and size of viruses but lack the genetic material necessary for replication. VLPs can be made from various proteins and used for multiple applications, including vaccines, drug delivery, and diagnostic assays. VLPs are composed of structural proteins that assemble into a three-dimensional structure that resembles a virus.
The structure of VLPs can be designed to mimic specific viral particles, allowing them to be used as a vaccine to induce an immune response against the virus. VLPs can also be engineered to carry drugs or other therapeutic agents, allowing them to be targeted to specific cells or tissues. As VLPs lack genetic material, they are non-infectious and do not pose a risk of causing disease. This makes them an attractive alternative to living attenuated vaccines, which contain inactive forms of the virus that can still cause illness in some individuals. VLPs have been used successfully in vaccines against hepatitis B and human papillomavirus (HPV). They are also being studied as potential vaccines for viruses, such as influenza, Zika, and Ebola.
VLPs are commonly used in research and development as a tool to study viral structure, function, and immune responses. VLPs can be produced using various techniques, including recombinant DNA technology and protein expression systems. One major advantage of using VLPs in research is that they are non-infectious and do not require specialized containment facilities, which makes them easier and safer to handle than live viruses. Additionally, VLPs can be used to study viral infection mechanisms and develop new vaccines and antiviral drugs.
[67565]
Virus-like Particles Market Dynamics
Increased demand and commercialization of VLPs-based vaccines primarily drive the global virus-like particles market. Virus-like particle-based vaccines have several advantages over traditional vaccines, including their ability to induce strong immune responses without the risk of causing disease. Additionally, recombinant DNA technology can produce them quickly and efficiently, making them a promising option for preventing infectious diseases. For instance, vaccines containing influenza VLPs are highly immunogenic, with superior protection against homologous viral infection compared to split vaccination. Moreover, increasing research and development activities of VLPs-based viral vaccines will fuel the market revenue share in the forecast years.
The Hepatitis B core (HBc) antigen has been approved. It is considered one of the popular commercial vaccines against hepatitis B due to its ability to assemble into VLPs capable of eliciting significant immune responses. HBc VLPs have also been utilized to generate vaccines against influenza A and foot-and-mouth disease by serving as a platform for presenting foreign epitopes to the immune system. Plant expression systems are fast, scalable, and safe, and they can provide accurate post-translational alterations while lowering upstream production costs. Creating HBc-based VLPs in plants would considerably improve vaccine production efficiency.
Increased usage of VLPs as delivery vehicles for gene editing is increasing its demand in research and development. This is because of their safety, immunogenicity, specificity, scalability, and stability. VLPs are a viable platform for gene therapy. Furthermore, VLPs can be engineered to deliver gene-editing tools, such as CRISPR-Cas9, into cells without the risk of causing disease. These VLPs also deliver the CRISPR-Cas9, allowing for precise gene editing. These particles have shown promising results in treating genetic diseases and developing new therapies.
However, many technical challenges in the purification, design, and storage of VLPs and complications associated with the manufacturing of VLPs, coupled with the high cost and time required for downstream processing of VLPs, can impede the market potential.
Virus-like Particles Market Ecosystem
The global virus-like particles market is analyzed from four perspectives: type, source, application, and region.
Virus-Like Particles Market by Type
[436745]
The global virus-like particles market is segmented into vaccines and therapeutics based on type.
The vaccine segment dominates the global virus-like particles market. VLP-based vaccines are one of the most promising therapeutic options due to their inherent immunogenicity and safety. VLPs are non-infectious, multimeric antigens with a particulate form that can instigate a safe and efficient humoral and cellular immune response. VLP vaccinations have been proven to be beneficial in the veterinary industry. VLPs comprise one or more structural proteins and lack native viral genomes and the capacity to self-replicate in cells. Moreover, the segment is anticipated to continue its dominance as many market players heavily invest in VLP vaccines.
The therapeutics segment is expected to show lucrative growth during the forecast period. VLPs in the form of therapeutics are engineered to mimic the structure of viruses without causing disease, making them a promising tool for drug delivery and immunotherapy. They can target specific cells and tissues, making them highly effective in treating various chronic diseases.
Virus-like Particles Market by Source
Based on source, the global virus-like particles market is segmented into yeast, plant, insect cell, and others.
The yeast segment accounts for the majority of the global virus-like particles market revenue share. This is because yeast provides advantages, such as scalable fermentation, reduced risk of contamination by adventitious organisms, low production costs, and the capacity to create VLPs with consistent quality. It is widely accepted that yeast may make VLPs with simple structures that are synthesized intracellularly. However, recent efforts have been made to expand its applicability. There is no evidence that it may be employed as an expression platform for creating VLPs from nonenveloped and enveloped viruses. Moreover, researchers suggest that yeast permits secretory VLP synthesis. Meanwhile, it has become evident that the plasmid and promoter used and the ratio of structural proteins generated impact the quality and amount of yeast-derived VLPs.
Virus-like Particles Market by Application
Based on application, the global virus-like particles market is segmented into hepatitis, Gaucher disease, cancer/HPV, and others.
The hepatitis segment accounted for the majority of the market revenue share in 2022. This is majorly attributed to the increasing prevalence of hepatitis. According to the World Health Organization (WHO) evaluations in 2022, an estimated 1.5 million cases of hepatitis A occur worldwide each year. VLPs have shown promising results in treating hepatitis B and C infections. VLPs mimic the structure of the virus, triggering an immune response without causing disease, making them safe and effective vaccine candidates. VLPs in hepatitis treatment can offer a versatile method to treat hepatitis infections. Additionally, the increasing research and development in the VLPs field will increase the demand to treat hepatitis in the forecast years.
Virus-like Particles Market by Region
Based on the region, the global virus-like particles market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominates the virus-like particles market with the largest revenue share. This is attributed to the increasing rates of addiction in the region. The factors driving the VLPs market in North America include the increasing prevalence of chronic diseases, rising demand for vaccines, and growing awareness about the benefits of immunization. Government initiatives to promote vaccination programs and the development of advanced technologies are also contributing to the growth of the VLPs market in North America.
The Europe virus-like particles market is characterized by increased awareness and usage of VLPs in pharmaceutical and biotechnology companies. One of the major factors driving the VLPs market in Europe is the increasing demand for vaccines to prevent infectious diseases. Additionally, the market is rising due to the high prevalence of chronic diseases, which has increased the demand for therapeutic vaccines. Moreover, increased fundings for developing a vaccine in the region also influence the virus-like particles market in Europe. For instance, to address COVID-19, the European Union 2020 made emergency funds available to help with research and development for diagnostics, treatments, and vaccinations. Initially, US$10 million was granted for research studies in response to the COVID-19 pandemic, which was later expanded to US$47.5 million. Moreover, the European Institute of Technology Health launched in April 2020 was a call to EIT partners to submit ideas for COVID-19 initiatives with strong implementation and finance for each project.
Asia Pacific is predicted to be the fastest-growing geographic region in the virus-like particles market over the forecast period. This growth can be attributed to the increasing research and development in influencing the global virus-like particles market in the Asia Pacific. Moreover, the Asia Pacific virus-like particles market is driven by expanding potential applications in therapeutics and diagnostics, the increasing importance of VLPs in therapeutic development and investigations, and the rising prevalence of infectious viral infections.
Virus-like Particles Market Competitive Landscape
The prominent companies with the largest revenue share in the global virus-like particles market are:
The global virus-like particles market is expected to grow at a revenue CAGR of 7.85% during the forecast period.
GlaxoSmithKline plc., Dynavax Technologies Corporation, Sanofi S.A., and Pfizer Inc. are among the key players in the global virus-like particles market.
The hepatitis segment accounts for the largest global virus-like particles market revenue share.
Asia Pacific is expected to observe the highest global virus-like particle market revenue growth during the forecast period.
The global virus-like particles market was valued at US$ 4.96 billion in 2022.
*Insights on financial performance are subject to the availability of information in the public domain